Successful tech transfer can be a challenge, even for well-established biotechs. Here’s how to avoid common pitfalls at every stage.
Modernized data governance ensures a solid foundation of data integrity and compliance and achieves an integrated approach to the BioPharma data lifecycle.
Speeding up time to insight throughout the BioPharma lifecycle requires all data sources to be connected and utilized to form a robust data backbone.
Life science companies rely on data integrity, security and transparency to ensure success. How do we protect data while keeping it accessible?
IDBS, a global life sciences software company and the leading innovator in BioPharma Lifecycle Management (BPLM), is excited to bring together over 200 customers, partners and industry experts, including leading CxO and BioPharma companies, at their annual i3 user conference.
In the quest to develop the science and raise funding, developing a digital strategy in general is an afterthought for fledgling biotech companies – if it’s considered at all. Not paying attention to it early, however, can hamper their ability to advance their science and constrain their revenue-generation options.
A legacy system approach isn’t suitable for modern BioPharma development. Here are four reasons why.
Modern BioPharma development requires more than just a LIMS and spreadsheets. Learn why in this article by Alberto Pascual, IDBS, featuring Accenture and published in Lab Manager.
IDBS announces the latest release of its Skyland PIMS software, which seamlessly combines product, process, and patient data across the BioPharma life cycle and supply chain, providing insights that accelerate process understanding and ensure product quality.
Compared to most other industries, life science and biopharmaceutical companies have been slow to embrace digital technologies. Why?
Life science companies need to harness the predictive value of data to drive deeper process understanding. Here’s how.
As the biopharmaceutical industry begins to embrace advanced data collection and analysis tools, it finds itself facing a challenging question: How can drug manufacturers best harness all that data to improve capacity, reduce bottlenecks and cut costs?